OSUR — ORASURE TECHNOLOGIES INC

—
Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 1116463 ·
Last close
$3.51
Market Cap
$242.36M
52W High
$4.58
52W Low
$2.08
ADV30
624,706
Next earnings
2026-11-09
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally. It offers OraQuick Rapid HIV test, OraQuick HIV self-test, OraQuick HIV self-test(international), OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, SickleSCAN test, and OraSure oral fluid collection device for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. The company also provides genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of urine samples; and HEMAcollect protein blood collection device. In addition, it provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; OMNIgene SALIVA DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Further, it offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Additionally, it develops a molecular self-test for chlamydia trachomatis and neisseria gonorrhoeae. It sells its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, and companion animal, markets. The company was founded in 1987 and is headquartered in Bethlehem, Pennsylvania.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 30,907,000 13,969,000 -12,209,000 -13,094,000 349,466,000 148,238,000 42,333,000
Jun 2026 30,639,000 13,317,000 -17,153,000 6,249,000 360,552,000 160,582,000 42,775,000
Mar 2026 27,925,000 11,804,000 -23,176,000 -22,377,000 379,169,000 176,964,000 65,845,000
Dec 2025 26,763,000 10,968,000 -16,852,000 -19,286,000 403,168,000 199,278,000 62,341,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-43,684,000
Investing CF
$-9,418,000
Financing CF
$-13,678,000
CapEx
$-5,937,000
Dividends Paid
—
Buybacks
$-13,882,000
EPS Diluted TTM
$-0.69
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-201,384,000
Inventory
$30,420,000
Receivables
$31,817,000
ST Investments
—
EBIT TTM
$-69,390,000
Pretax Income TTM
$-45,122,000
Interest Exp TTM
—
Analysts
2

Yahoo Snapshot (yfinance, live)

Total Revenue
$116,234,000
EBITDA
$-58,307,000
Free Cash Flow
$-47,510,752
Enterprise Value
$113,360,104
Total Cash
$148,238,000
Total Debt
$11,647,000
Shares Out
69,047,266
Trailing EPS
$-0.69
Book Value
$4.45
ROE
-14.5%
ROA
-10.9%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 115,021,000 -68,124,000 -68,731,000 403,168,000 62,341,000 340,827,000 -49,023,000
Dec 2024 185,827,000 -23,858,000 -19,500,000 479,659,000 69,321,000 410,338,000 27,374,000
Dec 2023 405,472,000 43,414,000 53,655,000 482,845,000 52,174,000 430,671,000 141,583,000
Dec 2022 387,479,000 -5,243,000 -17,133,000 444,180,000 79,755,000 364,425,000 -47,202,000

TTM Snapshot

Revenues TTM
$112,412,000
NetIncome TTM
$-49,126,000
OpCashFlow TTM
—
Assets (Latest)
$360,552,000
Forward EPS
$-0.48

Max Pain — expiry 2027-01-15

max pain strike: $2.50 · spot: $3.59 · call oi: 3,624 · put oi: 11
Expected Move to 2027-01-15: ±$1.48 (41.09%) — implied range $2.11 – $5.06 · ATM straddle on $2.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ZJYL Jin Medical International Ltd. $248.61M $3.38 —
CLPT ClearPoint Neuro, Inc. $251.95M $7.86 —
PROF Profound Medical Corp. $259.32M $7.08 —
SSII SS Innovations International, Inc. $266.51M $1.33 —
OFIX Orthofix Medical Inc. $271.87M $6.67 —

News headlines (Yahoo Finance, 1h cache)

OraSure Technologies (OSUR) Sees Activist Pressure Ease After Reaching Agreement with Altai Capital
2026-11-10 18:49 · Yahoo
OraSure (OSUR) Q3 2026 Earnings Call Transcript
2026-11-10 14:43 · Yahoo
OraSure Technologies, Inc. Q3 2026 Earnings Call Summary
2026-11-10 13:30 · Yahoo
OraSure Technologies Q3 Earnings Call Highlights
2026-11-10 01:14 · Yahoo
OraSure: Q3 Earnings Snapshot
2026-11-09 22:17 · Yahoo
OraSure Announces Third Quarter 2026 Financial Results; Strategic Execution Drives Double-Digit Year-Over-Year Growth and Margin Expansion
2026-11-09 21:05 · Yahoo
OraSure Technologies (OSUR) Stock Fair Value Rises As Testing Funding Outlook Stabilizes
2026-11-03 14:09 · Yahoo
OraSure to Announce Third Quarter 2026 Financial Results and Host Earnings Call on November 9th
2026-10-26 20:05 · Yahoo
OraSure (OSUR) Returns To Profit, But Growth Remains Elusive
2026-09-06 11:48 · Yahoo
OraSure (OSUR) Q2 2026 Earnings Call Transcript
2026-08-13 00:15 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.